drugset / Trial / NCT01691534

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)

NCT01691534

Phase 2 Completed 105 enrolled Global Alliance for TB Drug Development
RandomizedParallel-groupSingle-blindTreatment

Summary

The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of TMC207 plus PA-824 plus Pyrazinamide plus Clofazimine, TMC207 plus PA-824 plus Pyrazinamide, TMC207 plus PA-824 plus Clofazimine alone, TMC207 plus Pyrazinamide plus Clofazimine, Pyrazinamide alone, Clofazimine alone, and standard first line TB treatment as per South African TB Guidelines (Rifafour e-275) as determined by the rate of change of log CFU per ml sputum over the time period Day 0-14 in participants with smear positive pulmonary tuberculosis (TB). A control group will receive standard treatment.

Timeline

Start
2012-10
Primary completion
2013-04
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bedaquiline Small molecule 200 mg Oral
Subject Clofazimine Small molecule 100 mg Oral
Subject Pretomanid Small molecule 200 mg Oral
Subject Pyrazinamide Small molecule 1500 mg Oral
Comparator Rifafour Unknown 275 mg